Raphael Pharmaceutical Secures New Patent Application
Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH), a cutting-edge biotechnology firm focused on cannabinoid research, has recently filed a provisional patent application with the United States Patent and Trademark Office. This innovative step aims to enhance treatment options for autoimmune diseases dominated by neutrophils.
Focus on Neutrophil-Dominant Autoimmune Diseases
The newly filed patent application emphasizes the use of Raphael Pharmaceutical's highly purified cannabinoid platform for treating various conditions including rheumatoid arthritis (RA), psoriatic arthritis, inflammatory bowel disease, systemic lupus erythematosus, and gout. These disorders present significant health challenges, and the Company's approach targets the underlying mechanisms that exacerbate these diseases.
Promising Clinical Study Results
In earlier studies, Raphael Pharmaceutical demonstrated positive results for its cannabinoid formulation specifically aimed at managing RA. Conducted under Institutional Review Board (IRB) approval, the study adhered to rigorous U.S. Food and Drug Administration (FDA) standards, ensuring safety and scientific integrity. Importantly, participants reported no adverse effects during the trial.
Collaboration with Leading Research Institutions
Raphael Pharmaceutical's provisional patent is titled “Raphael Pharmaceutical, Inc. / Rambam MedTech Formula for Treating Neutrophil-Dominant Autoimmune Diseases (including RA)” and was filed in partnership with the Medical Cannabis Research and Innovation Center at Rambam Health Care Campus. This collaboration, initiated in 2019, allows Raphael exclusive access to advanced cannabinoid research led by Dr. Igal Louria-Hayon, a noted authority in cannabinoid research.
Expert Insights on the Patent Filing
Shlomi Pilo, the President and CEO of Raphael Pharmaceutical, remarked on the significance of this milestone. “The filing of this provisional patent application marks a pivotal moment for us and our partner Rambam,” he stated. This filing not only safeguards their innovative technology but also propels them closer to launching their commercial product, known as "RaphaWell." This product is designed for targeted delivery within the RA community in the U.S., emphasizing accessibility and safety.
Potential of Cannabinoid Formulations
Dr. Louria-Hayon also highlighted the potential of Raphael's cannabinoid formula to provide a safe, effective treatment option that alleviates inflammation and severe symptoms associated with rheumatoid arthritis. The provisional patent reflects their belief that this highly purified cannabinoid formulation could extend its benefits to other chronic inflammatory conditions.
About Raphael Pharmaceutical Inc.
Raphael Pharmaceutical Inc. (OTCQB: RAPH) is on the forefront of developing cannabinoid-based therapies free from THC and CBD to treat inflammatory diseases. Their lead product, RaphaWell, is a refined cannabinoid formulation specifically designed for oral delivery to enhance patient accessibility while ensuring a high safety profile with no reported side effects.
Frequently Asked Questions
What is the focus of Raphael Pharmaceutical's new patent application?
The patent application focuses on using Raphael's cannabinoid platform to treat neutrophil-dominant autoimmune diseases like rheumatoid arthritis.
What were the findings of the clinical study related to RA?
The study revealed significant improvements in pain, sleep quality, and overall well-being for participants, with benefits noticeable by week four.
Who collaborated with Raphael Pharmaceutical on this patent filing?
Raphael collaborated with the Medical Cannabis Research and Innovation Center at Rambam Health Care Campus for this filing.
What is the main product being developed by Raphael Pharmaceutical?
Raphael is developing RaphaWell, an orally delivered cannabinoid formulation focused on treating rheumatoid arthritis.
Where can I find more information about Raphael Pharmaceutical?
For more information, visit Raphael Pharmaceutical's website.
